Endothelins in health and disease

European Journal of Internal Medicine

Volumn 18, Issue 4, 2007, Pages 272-282

  Shah, Rahman ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Endothelins; Vasoactive agents; Vasoconstriction

Indexed keywords

AMBRISENTAN; BOSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; SITAXSENTAN; TEZOSENTAN; VASOCONSTRICTOR AGENT;

ATHEROSCLEROSIS; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; HEART DISEASE; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY FAILURE; NONHUMAN; PULMONARY HYPERTENSION; REVIEW; SEPSIS; VASCULAR ENDOTHELIUM;

EID: 34250170881     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2007.04.002     Document Type: Review

References (125)

1. Lerman A., and Zeiher A.M. Endothelial function: cardiac events. Circulation 111 (2005) 363-368
2. Hickey K., Rubanyi G., Paul R., and Highsmith R. Characterization of a coronary vasoconstrictor produced by cultured vascular endothelial cells. Am J Physiol 248 (1985) C550-C556
3. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988) 411-415 [see comment]
4. Davenport A.P. International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev 54 (2002) 219-226
5. Masaki T., Kimura S., Yanagisawa M., and Goto K. Molecular and cellular mechanism of endothelin regulation. Implications for vascular function. Circulation 84 (1991) 1457-1468
6. Haynes W.G., and Webb D.J. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 16 (1998) 1081-1098
7. Levin E.R. Endothelins. N Engl J Med 333 (1995) 356-363
8. Haynes W.G., Hand M.F., Johnstone H.A., Padfield P.L., and Webb D.J. Direct and sympathetically mediated venoconstriction in essential hypertension. Enhanced responses to endothelin-1. J Clin Invest 94 (1994) 1359-1364
9. Nishimura M., Takahashi H., Matsusawa M., Ikegaki I., Sakamoto M., Nakanishi T., et al. Chronic intracerebroventricular infusions of endothelin elevate arterial pressure in rats. J Hypertens 9 (1991) 71-76
10. Xu D., Emoto N., Giaid A., Slaughter C., Kaw S., deWit D., et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 78 (1994) 473-485
11. Nakano A., Kishi F., and Ninami K. Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J Immunol (1997) 1987-1992
12. Miyauchi T., Suzuki N., Kurihara T., Yamaguchi I., Sugishita Y., Matsumoto H., et al. Endothelin-1 and endothelin-3 play different roles in acute and chronic alterations of blood pressure in patients with chronic hemodialysis. Biochem Biophys Res Commun 178 (1991) 276-281
13. Rolinski B., Sadri I., Bogner J., and Goebel F.D. Determination of endothelin-1 immunoreactivity in plasma, cerebrospinal fluid and urine. Res Exp Med 194 (1994) 9-24
14. Yoshimoto S., Ishizaki Y., Sasaki T., and Murota S. Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells. Stroke 22 (1991) 378-383
15. Ergul S., Parish D.C., Puett D., and Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 28 (1996) 652-655 [erratum appears in Hypertension 1997 Mar; 29(3):912]
16. Evans R.R., Phillips B.G., Singh G., Bauman J.L., and Gulati A. Racial and gender differences in endothelin-1. Am J Cardiol 78 (1996) 486-488
17. Polderman K.H., Stehouwer C.D., van Kamp G.J., Dekker G.A., Verheugt F.W., and Gooren L.J. Influence of sex hormones on plasma endothelin levels. Ann Intern Med 118 (1993) 429-432
18. Schneider J.G., Tilly N., Hierl T., Sommer U., Hamann A., Dugi K., et al. Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens 15 (2002) 967-972
19. Hlubocka Z., Umnerova V., Heller S., Peleska J., Jindra A., Jachymova M., et al. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors. J Hum Hypertens 16 (2002) 557-562 [see comment]
20. Love M.P., Haynes W.G., Gray G.A., Webb D.J., and McMurray J.J. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 94 (1996) 2131-2137
21. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., Sanchez-Pascuala R., Hernandez G., Diaz C., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101 (1998) 2711-2719
22. Nakamura T., Ushiyama C., Hirokawa K., Osada S., Shimada N., and Koide H. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol 21 (2001) 449-454
23. Verma S., Rao V., Weisel R.D., Li S.-H., Fedak P.W.M., Miriuka S., et al. Novel cardioprotective effects of pravastatin in human ventricular cardiomyocytes subjected to hypoxia and reoxygenation: beneficial effects of statins independent of endothelial cells. J Surg Res 119 (2004) 66-71
24. Seljeflot I., Arnesen H., Andersen P., Aspelin T., and Kierulf P. Effects of doxazosin and atenolol on circulating endothelin-1 and von Willebrand factor in hypertensive middle-aged men. J Cardiovasc Pharmacol 34 (1999) 584-588
25. Garlichs C.D., Zhang H., Mugge A., and Daniel W.G. Beta-blockers reduce the release and synthesis of endothelin-1 in human endothelial cells. Eur J Clin Invest 29 (1999) 12-16
26. Krum H., Gu A., Wilshire-Clement M., Sackner-Bernstein J., Goldsmith R., Medina N., et al. Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Am Heart J 131 (1996) 337-341
27. Stangl K., Dschietzig T., Richter C., Laule M., Stangl V., Tanis E., et al. Pulmonary release and coronary and peripheral consumption of big endothelin and endothelin-1 in severe heart failure: acute effects of vasodilator therapy. Circulation 102 (2000) 1132-1138
28. Williams Jr. D.L., Jones K.L., Colton C.D., and Nutt R.F. Identification of high affinity endothelin-1 receptor subtypes in human tissues. Biochem Biophys Res Commun 180 (1991) 475-480
29. Arai H., Hori S., Aramori I., Ohkubo H., and Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348 (1990) 730-732 [see comment]
30. Verhaar M.C., Strachan F.E., Newby D.E., Cruden N.L., Koomans H.A., Rabelink T.J., et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 97 (1998) 752-756
31. Davenport A.P., and Maguire J.J. Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans?. Trends Pharmacol Sci 15 (1994) 9-11 [see comment]
32. Takuwa Y., Kasuya Y., Takuwa N., Kudo M., Yanagisawa M., Goto K., et al. Endothelin receptor is coupled to phospholipase C via a pertussis toxin-insensitive guanine nucleotide-binding regulatory protein in vascular smooth muscle cells. J Clin Invest 85 (1990) 653-658
33. Cocks T.M., Broughton A., Dib M., Sudhir K., and Angus J.A. Endothelin is blood vessel selective: studies on a variety of human and dog vessels in vitro and on regional blood flow in the conscious rabbit. Clin Exp Pharmacol Physiol 16 (1989) 243-246
34. Suzuki S., Kajikuri J., Suzuki A., and Itoh T. Effects of endothelin-1 on endothelial cells in the porcine coronary artery. Circ Res 69 (1991) 1361-1368
35. de Nucci G., Thomas R., D'Orleans-Juste P., Antunes E., Walder C., Warner T.D., et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proceedings of the National Academy of Sciences of the United States of America vol. 85 (1988) 9797-9800
36. Yang Z.H., Richard V., von Segesser L., Bauer E., Stulz P., Turina M., et al. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm?. Circulation 82 (1990) 188-195
37. Cockcroft J.R., Clarke J.G., and Webb D.J. The effect of intra-arterial endothelin on resting blood flow and sympathetically mediated vasoconstriction in the forearm of man. Br J Clin Pharmacol 31 (1991) 521-524
38. Davie N., Haleen S.J., Upton P.D., Polak J.M., Yacoub M.H., Morrell N.W., et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 165 (2002) 398-405
39. Chua B.H., Krebs C.J., Chua C.C., and Diglio C.A. Endothelin stimulates protein synthesis in smooth muscle cells. Am J Physiol 262 (1992) E412-E416
40. Hofman F.M., Chen P., and Jeyaseelan R. Endothelin-1 induces production of the neutrophil chemotactic factor interleukin-8 by human brain-derived endothelial cells. Blood 92 (1998) 3064-3072
41. Pedram A., Razandi M., Hu R.M., and Levin E.R. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol Chem 272 (1997) 17097-17103
42. Park J.B., and Schiffrin E.L. ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 37 (2001) 1444-1449
43. Haynes W.G., Ferro C.J., O'Kane K.P., Somerville D., Lomax C.C., and Webb D.J. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 93 (1996) 1860-1870
44. Haynes W.G., and Webb D.J. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344 (1994) 852-854 [see comment]
45. Galie N., Manes A., and Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 61 (2004) 227-237
46. Pieske B., Beyermann B., Breu V., Loffler B.M., Schlotthauer K., Maier L.S., et al. Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium. Circulation 99 (1999) 1802-1809
47. McMurray J.J., Ray S.G., Abdullah I., Dargie H.J., and Morton J.J. Plasma endothelin in chronic heart failure. Circulation 85 (1992) 1374-1379
48. Clavell A.L., Mattingly M.T., Stevens T.L., Nir A., Wright S., Aarhus L.L., et al. Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. J Clin Invest 97 (1996) 1286-1292
49. Parker J.D., and Thiessen J.J. Increased endothelin-1 production in patients with chronic heart failure. Am J Physiol Heart Circ Physiol 286 (2004) H1141-H1145
50. Tsutamoto T., Wada A., Maeda Y., Adachi T., and Kinoshita M. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 23 (1994) 1427-1433
51. Pacher R., Stanek B., Hulsmann M., Koller-Strametz J., Berger R., Schuller M., et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 27 (1996) 633-641
52. Pousset F., Isnard R., Lechat P., Kalotka H., Carayon A., Maistre G., et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 18 (1997) 254-258
53. Hulsmann M., Stanek B., Frey B., Sturm B., Putz D., Kos T., et al. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 32 (1998) 1695-1700
54. Anand I., McMurray J., Cohn J.N., Konstam M.A., Notter T., Quitzau K., et al. Investigators E: Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 347-354
55. O'Connor C.M., Gattis W.A., Adams Jr. K.F., Hasselblad V., Chandler B., Frey A., et al. Randomized Intravenous TeZosentan Study I: Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol 41 (2003) 1452-1457 [see comment]
56. Vierhapper H., Wagner O., Nowotny P., and Waldhausl W. Effect of endothelin-1 in man. Circulation 81 (1990) 1415-1418
57. Krum H., Viskoper R.J., Lacourciere Y., Budde M., and Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 338 (1998) 784-790 [see comment]
58. Taddei S., Virdis A., Ghiadoni L., Sudano I., Notari M., and Salvetti A. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation 100 (1999) 1680-1683
59. Hirai Y., Adachi H., Fujiura Y., Hiratsuka A., Enomoto M., and Imaizumi T. Plasma endothelin-1 level is related to renal function and smoking status but not to blood pressure: an epidemiological study. J Hypertens 22 (2004) 713-718
60. Abdel-Sayed S., Nussberger J., Aubert J.F., Gohlke P., Brunner H.R., and Brakch N. Measurement of plasma endothelin-1 in experimental hypertension and in healthy subjects. Am J Hypertens 16 (2003) 515-521
61. Ajne G., Wolff K., Fyhrquist F., Carlstrom K., Hemsen-Mortberg A., and Nisell H. Endothelin converting enzyme (ECE) activity in normal pregnancy and preeclampsia. Hypertens Pregnancy 22 (2003) 215-224
62. Ferri C., Bellini C., Desideri G., Mazzocchi C., De Siati L., and Santucci A. Elevated plasma and urinary endothelin-I levels in human salt-sensitive hypertension. Clin Sci 93 (1997) 35-41
63. Kaddoura S., Firth J.D., Boheler K.R., Sugden P.H., and Poole-Wilson P.A. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist. Circulation 93 (1996) 2068-2079
64. Lariviere R., and Lebel M. Endothelin-1 in chronic renal failure and hypertension. Can J Physiol Pharmacol 81 (2003) 607-621
65. Haak T., Marz W., Jungmann E., Hausser S., Siekmeier R., Gross W., et al. Elevated endothelin levels in patients with hyperlipoproteinemia. Clin Investig 72 (1994) 580-584
66. Cardillo C., Kilcoyne C.M., Cannon III R.O., and Panza JA. Increased activity of endogenous endothelin in patients with hypercholesterolemia. J Am Coll Cardiol 36 (2000) 1483-1488
67. Lerman A., Holmes Jr. D.R., Bell M.R., Garratt K.N., Nishimura R.A., and Burnett Jr. JC. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 92 (1995) 2426-2431
68. Mitani H., Takimoto M., Bandoh T., and Kimura M. Increases of vascular endothelin-converting enzyme activity and endothelin-1 level on atherosclerotic lesions in hyperlipidemic rabbits. Eur J Pharmacol 387 (2000) 313-319
69. Kowala M.C., Rose P.M., Stein P.D., Goller N., Recce R., Beyer S., et al. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol 146 (1995) 819-826
70. Boulanger C.M., Tanner F.C., and Bea M.L. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res 70 (1992) 1191-1197
71. Luscher T.F., and Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102 (2000) 2434-2440
72. Ihling C., Szombathy T., Bohrmann B., Brockhaus M., Schaefer H.E., and Loeffler B.M. Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis. Circulation 104 (2001) 864-869
73. Lerman A., Edwards B.S., Hallett J.W., Heublein D.M., Sandberg S.M., and Burnett Jr. J.C. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 325 (1991) 997-1001
74. Rossi G.P., Colonna S., Pavan E., Albertin G., Della Rocca F., Gerosa G., et al. Endothelin-1 and its mRNA in the wall layers of human arteries ex vivo. Circulation 99 (1999) 1147-1155
75. Hasdai D., Holmes Jr. D.R., Garratt K.N., Edwards W.D., and Lerman A. Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo. Circulation 95 (1997) 357-362
76. Zeiher A.M., Ihling C., Pistorius K., Schachinger V., and Schaefer H.E. Increased tissue endothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes. Lancet 344 (1994) 1405-1406
77. Minamino T., Kurihara H., Takahashi M., Shimada K., Maemura K., Oda H., et al. Endothelin-converting enzyme expression in the rat vascular injury model and human coronary atherosclerosis. Circulation 95 (1997) 221-230 [erratum appears in Circulation 1997 Apr 1;95(7):1975]
78. Bohm F., Ahlborg G., and Pernow J. Endothelin-1 inhibits endothelium-dependent vasodilatation in the human forearm: reversal by ETA receptor blockade in patients with atherosclerosis. Clin Sci 102 (2002) 321-327
79. Verma S., Lovren F., Dumont A.S., Mather K.J., Maitland A., Kieser T.M., et al. Endothelin receptor blockade improves endothelial function in human internal mammary arteries. Cardiovasc Res 49 (2001) 146-151 [see comment]
80. Piatti P.M., Monti L.D., Conti M., Baruffaldi L., Galli L., Phan C.V., et al. Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes 45 (1996) 316-321
81. Ferri C., Carlomagno A., Coassin S., Baldoncini R., Cassone Faldetta M.R., Laurenti O., et al. Circulating endothelin-1 levels increase during euglycemic hyperinsulinemic clamp in lean NIDDM men. Diabetes Care 18 (1995) 226-233
82. Cardillo C., Campia U., Bryant M.B., and Panza J.A. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 106 (2002) 1783-1787
83. Mather K.J., Mirzamohammadi B., Lteif A., Steinberg H.O., and Baron A.D. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes 51 (2002) 3517-3523
84. Pollock D.M., and Pollock J.S. Endothelin and oxidative stress in the vascular system. Curr Vasc Pharmacol 3 (2005) 365-367
85. Hoffmann E., Assennato P., Donatelli M., Colletti I., and Valenti T.M. Plasma endothelin-1 levels in patients with angina pectoris and normal coronary angiograms. Am Heart J 135 (1998) 684-688
86. Ferri C., Bellini C., Desideri G., Baldoncini R., Properzi G., Santucci A., et al. Circulating endothelin-1 levels in obese patients with the metabolic syndrome. Exp Clin Endocrinol Diabetes 105 Suppl 2 (1997) 38-40
87. Ruef J., Moser M., Kubler W., and Bode C. Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells. Cardiovasc Pathol 10 (2001) 311-315
88. Mraiche F., Cena J., Das D., and Vollrath B. Effects of statins on vascular function of endothelin-1. Br J Pharmacol 144 (2005) 715-726
89. Wilasrusmee C., Da Silva M., Siddiqui J., Bruch D., Kittur S., Wilasrusmee S., et al. Role of endothelin-1 in microvascular dysfunction caused by cyclosporin A. J Am Coll Surg 196 (2003) 584-591
90. Weis M., Wildhirt S.M., Schulze C., Rieder G., Wilbert-Lampen U., Wolf W.P., et al. Endothelin in coronary endothelial dysfunction early after human heart transplantation. J Heart Lung Transplant 18 (1999) 1071-1079
91. Best P.J., McKenna C.J., Hasdai D., Holmes Jr. D.R., and Lerman A. Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia. Circulation 99 (1999) 1747-1752
92. Bohm F., Beltran E., and Pernow J. Endothelin receptor blockade improves endothelial function in atherosclerotic patients on angiotensin converting enzyme inhibition. J Intern Med 257 (2005) 263-271
93. Homma S., Miyauchi T., Sugishita Y., Goto K., Sato M., and Ohshima N. Vasoconstrictor effects of endothelin-1 on myocardium microcirculation studied by the Langendorff perfusion method: differential sensitivities among microvessels. Microvasc Res 43 (1992) 205-217
94. Wenzel R.R., Fleisch M., Shaw S., Noll G., Kaufmann U., Schmitt R., et al. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 98 (1998) 2235-2240
95. MacCarthy P.A., Pegge N.C., Prendergast B.D., Shah A.M., and Groves P.H. The physiological role of endogenous endothelin in the regulation of human coronary vasomotor tone. J Am Coll Cardiol 37 (2001) 137-143
96. Kinlay S., Behrendt D., Wainstein M., Beltrame J., Fang J.C., Creager M.A., et al. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation 104 (2001) 1114-1118
97. Kaski J.C., Elliott P.M., Salomone O., Dickinson K., Gordon D., Hann C., et al. Concentration of circulating plasma endothelin in patients with angina and normal coronary angiograms. Br Heart J 74 (1995) 620-624
98. Stewart D.J., Kubac G., Costello K.B., and Cernacek P. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol 18 (1991) 38-43
99. Omland T., Lie R.T., Aakvaag A., Aarsland T., and Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 89 (1994) 1573-1579 [see comment]
100. Zeiher A.M., Goebel H., Schachinger V., and Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 91 (1995) 941-947
101. Clozel M., Qiu C., Qiu C.-S., Hess P., and Clozel J.-P. Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction. J Am Coll Cardiol 39 (2002) 142-147
102. Kyriakides Z.S., Kremastinos D.T., Psychari S.N., Kolettis T., Sbarouni E., and Webb D.J. Coronary vasoconstriction after coronary angioplasty is attenuated by endothelin a receptor antagonism. Am J Cardiol 87 (2001) 1011-1013 [A1015]
103. Takase H., Sugiyama M., Nakazawa A., Toriyama T., Hayashi K., Goto T., et al. Increased endogenous endothelin-1 in coronary circulation is associated with restenosis after coronary angioplasty. Can J Cardiol 19 (2003) 902-906
104. Benigni A., and Remuzzi G. Endothelin antagonists. Lancet 353 (1999) 133-138
105. Goddard J., Johnston N.R., Hand M.F., Cumming A.D., Rabelink T.J., Rankin A.J., et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 109 (2004) 1186-1193
106. Kaasjager K.A.S.S., Koomans H.A., and Rabelink T.J. Role of endothelin receptor subtypes in the systemic and renal responses to endothelin-1 in humans. J Am Soc Nephrol 8 (1997) 32-39
107. Brooks D.P., DePalma P.D., and Gellai M. Nonpeptide endothelin receptor antagonists. III. Effect of SB 209670 and BQ123 on acute renal failure in anesthetized dogs. J Pharmacol Exp Ther 271 (1994) 1-7
108. Ziv I., Fleminger G., Djaldetti R., Achiron A., Melamed E., and Sokolovsky M. Increased plasma endothelin-1 in acute ischemic stroke. Stroke 23 (1992) 1014-1016
109. Kessler I.M., Pacheco Y.G., Lozzi S.P., de Araujo Jr. A.S., Onishi F.J., and de Mello P.A. Endothelin-1 levels in plasma and cerebrospinal fluid of patients with cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Surg Neurol 64 Suppl 1 (2005) S1:2-S1:5 discussion S1:5
110. Macrae I.M., Robinson M.J., Graham D.I., Reid J.L., and McCulloch J. Endothelin-1-induced reductions in cerebral blood flow: dose dependency, time course, and neuropathological consequences. J Cereb Blood Flow Metab 13 (1993) 276-284
111. Vatter H., Zimmermann M., Tesanovic V., Raabe A., Seifert V., and Schilling L. Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist shown to be clinically effective for the treatment of cerebral vasospasm. Part II: effect on endothelin(B) receptor-mediated relaxation. J Neurosurg 102 (2005) 1108-1114
112. Matsuo Y., Mihara S., Ninomiya M., and Fujimoto M. Protective effect of endothelin type A receptor antagonist on brain edema and injury after transient middle cerebral artery occlusion in rats. Stroke 32 (2001) 2143-2148
113. Stewart D.J., Levy R.D., Cernacek P., and Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?. Ann Intern Med 114 (1991) 464-469
114. Giaid A., Yanagisawa M., Langleben D., Michel R.P., Levy R., Shennib H., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328 (1993) 1732-1739 [see comment]
115. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903 [see comment][erratum appears in N Engl J Med 2002 Apr 18;346(16):1258]
116. Badesch D.B., Abman S.H., Ahearn G.S., Barst R.J., McCrory D.C., Simonneau G., et al. American College of Chest P: Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 (2004) 35S-62S
117. Barst R.J., Langleben D., Frost A., Horn E.M., Oudiz R., Shapiro S., et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169 (2004) 441-447 [see comment]
118. Sanai L., Haynes W.G., MacKenzie A., Grant I.S., and Webb D.J. Endothelin production in sepsis and the adult respiratory distress syndrome. Intensive Care Med 22 (1996) 52-56
119. Tschaikowsky K., Sagner S., Lehnert N., Kaul M., and Ritter J. Endothelin in septic patients: effects on cardiovascular and renal function and its relationship to proinflammatory cytokines. Crit Care Med 28 (2000) 1854-1860
120. Voerman H.J., Stehouwer C.D., van Kamp G.J., Strack van Schijndel R.J., Groeneveld A.B., and Thijs L.G. Plasma endothelin levels are increased during septic shock. Crit Care Med 20 (1992) 1097-1101
121. Kernochan L.E., Tran B.N., Tangkijvanich P., Melton A.C., Tam S.P., and Yee Jr. H.F. Endothelin-1 stimulates human colonic myofibroblast contraction and migration. Gut 50 (2002) 65-70
122. Mangiafico R.A., Malatino L.S., Attina T., Messina R., and Fiore C.E. Exaggerated endothelin release in response to acute mental stress in patients with intermittent claudication. Angiology 53 (2002) 383-390
123. Murch S.H., Braegger C.P., Sessa W.C., and MacDonald T.T. High endothelin-1 immunoreactivity in Crohn's disease and ulcerative colitis. Lancet 339 (1992) 381-385
124. Nelson J., Bagnato A., Battistini B., and Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 3 (2003) 110-116
125. Noll G., Wenzel R.R., Schneider M., Oesch V., Binggeli C., Shaw S., et al. Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation 93 (1996) 866-869 [see comment]